Table 2.
Association between mutation status and brain metastasis incidence and recurrence. WT: wild type; BM: brain metastases; *: significant p-value.
| BM Characteristics | Total n (%) | EGFR Mutant n (%) | KRAS Mutant n (%) | EGFR and KRAS WT n (%) | p-Value |
|---|---|---|---|---|---|
| BM Incidence | |||||
| Brain Metastasis | 0.031 * | ||||
| Yes | 81 (57.04) | 14 (87.50) | 26 (55.32) | 41 (51.90) | |
| No | 61 (42.96) | 2 (12.50) | 21 (44.68) | 38 (48.10) | |
| Synchronous | 52 (64.20) | 8 (57.14) | 18 (69.23) | 26 (63.41) | 0.741 |
| Metachronous | 29 (35.80) | 6 (42.86) | 8 (30.77) | 15 (26.59) | |
| Brain Metastasis Related Death | 0.528 | ||||
| Yes | 31 (42.26) | 7 (50.00) | 11 (44.00) | 13 (34.21) | |
| No | 46 (59.74) | 7 (50.00) | 14 (56.00) | 25 (65.79) | |
| BM Recurrence | |||||
| Recurrence | 0.047 * | ||||
| Yes n (%) | 41 (50.62) | 8 (57.14) | 8 (30.77) | 25 (60.98) | |
| No n (%) | 40 (49.38) | 6 (42.86) | 18 (69.23) | 16 (39.02) | |
| Time to Recurrence | 1.000 | ||||
| ≤12 months n (%) | 29 (70.73) | 6 (75.00) | 6 (75.00) | 17 (68.00) | |
| >12 months n (%) | 12 (29.27) | 2 (25.00) | 2 (25.00) | 8 (32.00) | |